G2M CANCER DRUGS AG has a total of 18 patent applications. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are NAKAO KAZUWA, SUPERLAB FAR EAST LTD and LANG FLORIAN.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Canada | 3 | |
#4 | United States | 2 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Measuring microorganism processes | |
#4 | Analysing materials | |
#5 | Peptides | |
#6 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Minucci Saverio | 11 |
#2 | Pelicci Pier Giuseppe | 11 |
#3 | Hentsch Bernd | 10 |
#4 | Heinzel Thorsten | 7 |
#5 | Maurer Alexander B | 6 |
#6 | Goettlicher Martin | 5 |
#7 | Groner Bernd | 4 |
#8 | Wels Winfried Stephan | 4 |
#9 | Golebiewski Martin | 4 |
#10 | Zhu Ping | 4 |
Publication | Filing date | Title |
---|---|---|
US2005176686A1 | Novel compounds as histone deacetylase inhibitors | |
EP1491188A1 | Topical use of valproic acid for the prevention or treatment of skin disorders | |
EP1403639A1 | Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases | |
EP1400806A1 | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity | |
EP1293205A1 | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |